After carefully reviewing the current knowledge, the use of CRMs might be recommended when a particular pathway, such as PI3K/AKT/mTOR or IGF1/IGFBP, is upregulated in the tumor and can be modulated by the intervention. The gene discussed is PIK3CG; the disease is neoplasm.